2016
Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer
Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2016, 152: 44-54.e9. PMID: 27131846, DOI: 10.1016/j.jtcvs.2016.03.060.Peer-Reviewed Original ResearchConceptsStage I lung cancerStereotactic body radiotherapyI lung cancerNational Cancer DatabaseClinical stage I lung cancerNon-small cell lung cancerCell lung cancerBody radiotherapyHealthy patientsLung cancerCancer DatabaseClinical stage I non-small cell lung cancerStage I non-small cell lung cancerBetter outcomesEarly-stage non-small cell lung cancerPatient healthCox proportional hazards modelComorbidity-free patientsClinical stage IPropensity-matched analysisProportional hazards modelLong-term survivalHealth-related reasonsStereotactic patientsT1N0M0 tumors
2013
Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population
Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population. CHEST Journal 2013, 143: 429-435. PMID: 23187634, PMCID: PMC3566996, DOI: 10.1378/chest.12-1149.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryProportion of patientsOlder patientsCancer careNon-small cell lung cancer careEarly-stage non-small cell lung cancerStage non-small cell lung cancerEnd Results-Medicare databaseLung cancer careCell lung cancerCurative local therapyNew treatment modalitiesOverall useNew surgical techniqueType of treatmentNew radiation modalitiesRadiation therapy modalitiesSurgical resectionCurative therapyLocal therapyMore patientsThoracoscopic surgeryMean age
2009
Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal 2009, 135: 1588-1595. PMID: 19188545, DOI: 10.1378/chest.08-1430.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPneumonectomyPreoperative CareProbabilityRespiratory Function TestsRisk AssessmentSurvival AnalysisConceptsNon-small cell lung cancerCell lung cancerSurgical resectionLung cancerPulmonary toxicityResectable early stage non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized phase 2 trialPulmonary function test resultsSecondary end pointsCombination of gemcitabinePhase 2 trialPulmonary function testsGemcitabine-based chemotherapyFunction test resultsTotal lung capacityEligible patientsNonplatinum regimensDyspnea scoreInterstitial pneumonitisPreoperative chemotherapyFunction testsSmoking statusClinical symptomsPreoperative setting
2008
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive Care In Cancer 2008, 17: 307-313. PMID: 18781341, DOI: 10.1007/s00520-008-0489-y.Peer-Reviewed Original ResearchConceptsLung Cancer Symptom ScaleNon-small cell lung cancerQuality of lifeCancer Symptom ScaleCell lung cancerNeoadjuvant therapyPostsurgical evaluationLung cancerSymptom ScaleEarly-stage non-small cell lung cancerStage non-small cell lung cancerClinical stage IECOG performance statusSubgroup of patientsModalities of treatmentSignificant survival gainStable QOLConclusionsMost patientsNeoadjuvant trialsAdjuvant approachPerformance statusPreoperative chemotherapyComplete resectionStable symptomsSurvival gainNeoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival